Characteristics and predictors of antipsychotic medication off-label use among community-dwelling older people

View at publisher
Authors: Tuomas Majuri, Jenni Silvan, Anna-Maija Tolppanen, Sirpa Hartikainen, Taina Huotari, Nina Rautio, Jouko Miettunen, Tanja Nordström, Erika Jääskeläinen, Marianne Haapea
Cited by: 1
References: 46

Abstract

Background Concerns have been raised regarding the common off-label use of antipsychotic (AP) medications among older adults. However, comprehensive knowledge of the determinants of AP off-label use in this population remains limited.Methods We examined characteristics and predictors of AP off-label use in a nationwide Finnish cohort of community-dwelling older adults with psychiatric morbidity—but without Alzheimer’s disease—using longitudinal register data on sociodemographic and illness-related factors. The sample comprised four groups: those prescribed APs off-label (n = 20,563), those with non-psychotic mental disorders without off-label APs (CG1, n = 22,891), those with psychosis or bipolar disorder with APs (CG2, n = 8,966), and those with psychosis or bipolar disorder without APs (CG3, n = 4,585). Sociodemographic and illness-related factors were compared between the off-label and the comparison groups using logistic regression.Results Compared to comparison groups, individuals with off-label use more frequently had cardiovascular diseases and strokes. Compared to CG1 and CG3, individuals with AP off-label use were more often female, had a lower prevalence of asthma/chronic obstructive pulmonary disease, and a higher use of psychotropic medications and opioids. Compared to CG2, individuals with off-label use were more often male and had a lower prevalence of diabetes, epilepsy, as well as a lower use of psychotropic medications and a higher use of opioids. Risperidone (43%) and quetiapine (39%) were the most used APs off-label.Conclusion Alternative treatments are needed to curb off-label AP use among community-dwelling older adults, given the high prevalence of cardiovascular disease and stroke. Monitoring guidelines are needed to promote safer prescribing practices.

Fields of Study & Subjects

Pharmaceutical studies and practices Schizophrenia research and treatment Attention Deficit Hyperactivity Disorder

Publication details

Journal / source
Nordic Journal of Psychiatry
Publisher
Informa UK Limited
Volume
80
Issue
3
Pages
167–176
Publication date
16 February 2026
Language
EN